Omega Therapeutics, Inc.
OMGADelisted Mar 20, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850838
Omega Therapeutics, Inc. was delisted on Mar 20, 2025; its insiders filed their last Form 4 on Dec 5, 2024; 53 institutions reported holding it in 13F filings for Q4 2024, worth $35.3M in total; no superinvestor held it.
Holders of 5% or more of OMGA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Omega Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Flagship V VentureLabs Rx Fund, L.P. | 13D/A | 52.80%29.2M shares | – | Feb 5, 20251 filing | Feb 5, 2025 | SEC |
| Flagship Ventures Fund V, L.P. | 13D/A | 52.80%29.2M shares | – | Dec 31, 20241 filing | Dec 31, 2024 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Omega Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 7, 20259:57 AM ET | FMR LLCand 1 other | 13G/A | 0.00%0 shares | –Below 5% | Feb 28, 2025 | SEC |
| Feb 5, 20254:40 PM ET | Flagship V VentureLabs Rx Fund, L.P.and 16 others | 13D/A | 52.80%29.2M shares | – | Feb 3, 2025 | SEC |
| Dec 31, 20245:37 PM ET | Flagship Ventures Fund V, L.P.and 16 others | 13D/A | 52.80%29.2M shares | – | Dec 29, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Omega Therapeutics, Inc. shares.
No Form 144 notices for Omega Therapeutics, Inc. are on file.